By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

With a $2-billion cancer drug deal in its pocket, Glenmark’s licensing agreement with AbbVie not only unlocks a potential ...

Shares of Glenmark Pharmaceuticals surged 14% to an all-time high on Friday after its biotechnology unit, Ichnos Glenmark ...

Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

Motilal Oswal said the deal validates several aspects of Glenmark Pharma such as the strength of IGI's BEAT protein platform ...

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

The deal also entails $1.23 billion in milestone payments. While Glenmark unit IGI will retain rights for India and emerging ...

With a robust trading session and positive momentum, Glenmark is showing very bullish sentiment as per Moneycontrol analysis.

We’ve gone through blood, sweat, and tears to get here. This validates everything we’ve built,' Saldanha says as Glenmark ...

HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama ...

The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and ...